文献速递甲状腺与浅表介入US

超声引导热消融治疗良性甲状腺结节与低风险滤泡性肿瘤的疗效与安全性比较:单中心回顾性研究

Comparative Efficacy and Safety of Ultrasound-Guided Thermal Ablation for Benign Thyroid Nodules versus Low-Risk Follicular Neoplasms: A Single-Center Retrospective Study.
PubMed 文献 · Acad Radiol · 2025-07-22

此项单中心回顾性研究纳入1900例接受热消融的良性甲状腺结节或滤泡性甲状腺肿瘤患者,经倾向性评分匹配后每组各106例。两组技术成功率均为100%,12个月中位体积缩小率分别为86.7%和91.5%,疾病进展、无进展生存率、并发症及肿瘤消失率均无显著差异。结论认为热消融对两种病变可达到相当的安全性和有效性。

要点

  • 倾向性评分匹配后良性结节组与滤泡性肿瘤组各106例,技术成功率均为100%。
  • 12个月中位体积缩小率良性结节组86.7%,滤泡性肿瘤组91.5%。
  • 两组疾病进展、无进展生存率、并发症及肿瘤消失率均无显著差异。

核心结论

  • 热消融对良性甲状腺结节和滤泡性甲状腺肿瘤可达到相当的安全性和有效性结局。

研究设计与样本

  • 单中心回顾性研究,纳入2016年1月至2024年8月接受热消融的1900例良性甲状腺结节或滤泡性甲状腺肿瘤患者,按Bethesda分类分组,采用倾向性评分匹配控制混杂因素,匹配后每组各106例。

诊断标准与关键数值

  • 倾向性评分匹配后良性结节组106例(中位年龄45岁,IQR 36-56;女性90例),滤泡性肿瘤组106例(中位年龄46岁,IQR 34-58;女性87例)。
  • 良性结节组中位随访36个月(IQR 12-60),滤泡性肿瘤组中位随访35个月(IQR 18-49)。
  • 两组技术成功率均为100%;12个月中位体积缩小率良性结节组86.7%(IQR 62.5%-95.1%),滤泡性肿瘤组91.5%(IQR 64.3%-100%)。
  • 疾病进展良性结节组4.7% vs 滤泡性肿瘤组5.7%(P > 0.99);并发症良性结节组2.8% vs 滤泡性肿瘤组3.8%(P > 0.99);肿瘤消失良性结节组50.1% vs 滤泡性肿瘤组32.5%(P = 0.089)。
  • 无进展生存率:1年良性结节组95.8% vs 滤泡性肿瘤组99.1%(P = 0.449);3年良性结节组96.2% vs 滤泡性肿瘤组84.5%(P = 0.883);5年良性结节组93.1% vs 滤泡性肿瘤组96.2%(P = 0.594);总体良性结节组84.5% vs 滤泡性肿瘤组93.1%(P = 0.7)。

临床应用与阅片要点

  • 瞬时声音嘶哑是唯一的主要并发症。
  • 作者结论认为热消融对良性甲状腺结节和滤泡性甲状腺肿瘤可达到相当的安全性和有效性结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To compare the efficacy and safety of thermal ablation (TA) in the treatment of benign thyroid nodules (BTN) and follicular thyroid neoplasms (FTN).

MATERIALS AND METHODS: This retrospective study included 1900 patients with BTN or FTN who underwent TA between January 2016 and August 2024. Patients were categorized according to the Bethesda category, and propensity score matching (PSM) was employed to control for confounding factors. Kaplan-Meier curves were used to analyze disease progression and tumor disappearance.

RESULTS: After PSM (1:1), 106 patients (median age 45 years [IQR 36-56]; 90 women) were included in the BTN group, and 106 patients (median age 46 years [IQR 34-58]; 87 women) were included in the FTN group. The median follow-up durations were 36 months (IQR, 12-60) for the BTN group and 35 months (IQR, 18-49) for the FTN group. Technical success rates were 100% in both groups. The median volume reduction rates (VRR) at 12 months were 86.7% (IQR: 62.5%-95.1%) in the BTN group and 91.5% (IQR: 64.3%-100%) in the FTN group. No significant differences were observed between the BTN and FTN groups in disease progression (4.7% vs. 5.7%, P > 0.99), progression-free survival rates (1-year:95.8% vs. 99.1%, P = 0.449; 3-year: 96.2% vs. 84.5%, P = 0.883; 5-year: 93.1% vs. 96.2%, P = 0.594; overall: 84.5% vs. 93.1%, P = 0.7), complications (2.8% vs. 3.8%, P > 0.99), or tumor disappearance (50.1% vs. 32.5%, P = 0.089). Transient hoarseness was the only major complication.

CONCLUSION: TA could achieve comparable safety and efficacy outcomes for both BTN and FTN.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Liu YT, Wei Y, Zhao ZL, et al. Comparative Efficacy and Safety of Ultrasound-Guided Thermal Ablation for Benign Thyroid Nodules versus Low-Risk Follicular Neoplasms: A Single-Center Retrospective Study. Acad Radiol. 2025. PMID: 40695716. doi:10.1016/j.acra.2025.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。